ALK Kinase Domain Mutations in Primary Anaplastic Large Cell Lymphoma: Consequences on NPM-ALK Activity and Sensitivity to Tyrosine Kinase Inhibitors

ALK inhibitor crizotinib has shown potent antitumor activity in children with refractory Anaplastic Large Cell Lymphoma (ALCL) and the opportunity to include ALK inhibitors in first-line therapies is oncoming. However, recent studies suggest that crizotinib-resistance mutations may emerge in ALCL pa...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:PLoS One
Egile Nagusiak: Lovisa, Federica, Cozza, Giorgio, Cristiani, Andrea, Cuzzolin, Alberto, Albiero, Alessandro, Mussolin, Lara, Pillon, Marta, Moro, Stefano, Basso, Giuseppe, Rosolen, Angelo, Bonvini, Paolo
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Public Library of Science 2015
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4395299/
https://ncbi.nlm.nih.gov/pubmed/25874976
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0121378
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak